Rowan Chapman

Healthcare data is messy. We all know it. Datasets are often riddled with errors, inconsistencies and missing values, requiring data science teams to spend countless hours cleaning data before analyzing it. The Cornerstone AI assistant is purpose-built to clean RWD. Its proprietary machine learning models automatically generate unique clinically relevant data cleaning rules for every dataset. The Cornerstone AI assistant learns the structure and connections across data sources, harmonizing the structure. ML models then identify and correct errors, which are applied automatically or guided through our UI for optimal balance of scalability and nuance.

Reveal Cellular Choreography | See Biology in Motion Cellanome enables scientists to capture the intricacies of cells and their interactions, with the scale, resolution and context necessary to unravel biological complexity. Our live-cell analysis platform captures cellular dynamics at scale, integrating time-lapse imaging with single-cell transcriptomics to reveal how cells evolve, interact, and respond over time. This generates AI-ready datasets with the context and continuity needed to advance therapeutic development and mechanistic understanding across immunology, oncology, neuroscience, and aging.

Evidation creates new ways to measure and improve health in everyday life—making proactive, personalized, and truly human-centered healthcare possible. By connecting directly with millions of individuals, Evidation harnesses real-world data to deeply understand health experiences, rapidly and at scale. Evidation’s privacy-centric digital health measurement and engagement platform uses data science and machine learning to translate these everyday insights into high-impact health guidance, treatments, and tools. Founded in 2012, Evidation is headquartered in California with employees working around the globe.

At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California.

HealthTap is a tech-enabled virtual physician practice delivering accessible and cost-effective primary care with partners nationwide. We partner with health plans, health systems, IDNs, accountable care organizations (ACOs), at-risk providers, and employers to provide extremely cost-effective, quality virtual primary care in all 50 states with attractive fee-for-service or value-based care arrangements. Our proprietary and engaging platform integrates seamlessly into existing patient workflows, EMRs, and care channels. Patients served can choose and see the same doctor over time as well as enjoy same day/week appointments, fast doctor responses by text from their dedicated doctor, and 365-day urgent care with median wait time less than 1 minute. For more info, visit healthtap.com/partnerships/

Sequenta was acquired by Adaptive Biotechnologies (ow.ly/L8mCX) in January 2015. Visit adaptivebiotech.com or https://www.linkedin.com/company/adaptive-biotechnologies-corp- for the latest company news. Sequenta was a venture-backed biotechnology company dedicated to improving patient care in diseases mediated by immune cells through the discovery and development of novel clinical diagnostics. The company, located in South San Francisco, was founded in 2008.

As of January 1, 2014, Verinata Health has become part of the Reproductive and Genetic Health business unit under the Illumina parent company. As such, the Verinata Health name has changed to Illumina. The realignment of Verinata Health’s business under the Illumina brand name is part of a larger strategy to deliver comprehensive and integrated solutions to our customers serving the reproductive and genetic health market. This realignment will allow the company to more effectively focus their efforts on providing targeted products and services to meet the current and emerging needs of our community. Illumina is already the established leader in the development and commercialization of core sequencing technologies that are fueling the delivery of most non-invasive prenatal tests, and Illumina is committed to expanding its portfolio of offerings in the reproductive and genetic health area. Rest assured that while the name and look of some of the business components may change to Illumina, the underlying verifi® prenatal test services remains the same.

At Adamas, our mission and vision are clear: deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers, and society. We are a fully-integrated company focused on growing a portfolio of therapies to address a range of neurological diseases.

RainDance Technologies is making complex genetics simple. The company’s ultra-sensitive genomic tools enable research of novel non-invasive liquid biopsy applications that should result in more accurate, reliable, cost-effective, and early detection of cancer and other inherited and infectious diseases. Major research institutions and laboratories around the world rely on the performance of RainDance systems. Based outside Boston, Massachusetts, the company supports customers using RainDrop® Digital PCR, as well as the ThunderStorm® and ThunderBolts™ Next-Generation Sequencing Enrichment Systems through its international sales and service operations, as well as a global network of distributors and commercial service providers. Both technology platforms have been recognized by The Scientist as Top 10 Innovations with the RainDrop System winning the award in 2014 and the ThunderStorm System winning the award in 2011.

At PacBio, we’re devoted to empowering you. Pioneering the future through biology takes vision. You have to look beyond the status quo to what’s possible. We know your vision can reveal the full potential of the genome, advance human health and the health of our planet. And that is why your vision and pursuit are at the very center of what our company does — our product design, our customer support model, our partnerships, and even our identity. We create the world’s most advanced sequencing systems to provide you the most complete and accurate view of genomes, transcriptomes, and epigenomes. Our founders invented a new way to study the synthesis and regulation of DNA, RNA, and proteins. Driven by a desire to advance human health, we’re harnessing advances in biochemistry, optics, nanofabrication, and more. We are passionate about developing products that empower scientists to explore the full spectrum of genetic variation in any organism — from unraveling the mystery of rare diseases to improving the world’s food supply. With world-class service and support, we keep your research progressing so you can focus on finding answers. We encourage you to see the whole picture — and consider us the partner you trust to see it too.

Healthcare data is messy. We all know it. Datasets are often riddled with errors, inconsistencies and missing values, requiring data science teams to spend countless hours cleaning data before analyzing it. The Cornerstone AI assistant is purpose-built to clean RWD. Its proprietary machine learning models automatically generate unique clinically relevant data cleaning rules for every dataset. The Cornerstone AI assistant learns the structure and connections across data sources, harmonizing the structure. ML models then identify and correct errors, which are applied automatically or guided through our UI for optimal balance of scalability and nuance.

Venture Capital firm investing in early stage companies at the intersection of life sciences, engineering, and computation.

Cambridge Innovation Capital backs world-leading life sciences and technology companies with an affiliation to Cambridge, Europe’s leading capital for innovation. As a preferred investor for the University of Cambridge, we have unparalleled access to investment opportunities in the ecosystem. CIC currently manages over £500 million and has invested in 30+ companies. We invest in disruptive, deep-tech businesses in sectors including, but not limited to, artificial intelligence, internet of things, quantum technologies, autonomous systems, therapeutics, medtech/diagnostics, digital health and genomics/proteomics.

Reveal Cellular Choreography | See Biology in Motion Cellanome enables scientists to capture the intricacies of cells and their interactions, with the scale, resolution and context necessary to unravel biological complexity. Our live-cell analysis platform captures cellular dynamics at scale, integrating time-lapse imaging with single-cell transcriptomics to reveal how cells evolve, interact, and respond over time. This generates AI-ready datasets with the context and continuity needed to advance therapeutic development and mechanistic understanding across immunology, oncology, neuroscience, and aging.

INITIATE funds and co-creates transformational companies - We focus on bold ideas at the intersection of healthcare, life sciences and technology - We are entrepreneurs and investors who have founded numerous market-defining companies - We dedicate ourselves to only a few founding teams at a time and commit to their success